Functionalization of Ga-Radiolabeled Nanodiamonds with Octreotide Does Not Improve Tumor-Targeting Capabilities

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Apr 27

PMID 38675474

Authors

Thomas Wanek

Marco Raabe

Md Noor A Alam

Thomas Filip

Johann Stanek

Mathilde Loebsch

Christian Laube

Severin Mairinger

Tanja Weil

Claudia Kuntner

Affiliations

Soon will be listed here.

Abstract

Nanodiamonds (NDs) are emerging as a novel nanoparticle class with growing interest in medical applications. The surface coating of NDs can be modified by attaching binding ligands or imaging probes, turning them into multi-modal targeting agents. In this investigation, we assessed the targeting efficacy of octreotide-functionalized Ga-radiolabelled NDs for cancer imaging and compared it with the tumor uptake using [Ga]Ga-DOTA-TOC. In vivo studies in mice bearing AR42J tumors demonstrated the highest accumulation of the radiolabeled functionalized NDs in the liver and spleen, with relatively low tumor uptake compared to [Ga]Ga-DOTA-TOC. Our findings suggest that, within the scope of this study, functionalization did not enhance the tumor-targeting capabilities of NDs.

References

Lazovic J, Goering E, Wild A, Schutzendube P, Shiva A, Loffler J . Nanodiamond-Enhanced Magnetic Resonance Imaging. Adv Mater. 2023; 36(11):e2310109. DOI: 10.1002/adma.202310109. View

Perevedentseva E, Lin Y, Jani M, Cheng C . Biomedical applications of nanodiamonds in imaging and therapy. Nanomedicine (Lond). 2013; 8(12):2041-60. DOI: 10.2217/nnm.13.183. View

Taylor J, Theveniau M, Bashirzadeh R, Reisine T, Eden P . Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides. 1994; 15(7):1229-36. DOI: 10.1016/0196-9781(94)90146-5. View

Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, Schaffler M . Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm. 2011; 77(3):407-16. PMC: 3051057. DOI: 10.1016/j.ejpb.2010.12.029. View

Winter G, Eberhardt N, Loffler J, Raabe M, Alam M, Hao L . Preclinical PET and MR Evaluation of Zr- and Ga-Labeled Nanodiamonds in Mice over Different Time Scales. Nanomaterials (Basel). 2022; 12(24). PMC: 9780863. DOI: 10.3390/nano12244471. View

Wang D, Li Y, Tian Z, Cao R, Yang B . Transferrin-conjugated nanodiamond as an intracellular transporter of chemotherapeutic drug and targeting therapy for cancer cells. Ther Deliv. 2014; 5(5):511-24. DOI: 10.4155/tde.14.17. View

Ehlerding E, Grodzinski P, Cai W, Liu C . Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano. 2018; 12(3):2106-2121. PMC: 5878691. DOI: 10.1021/acsnano.7b07252. View

Zhang T, Cui H, Fang C, Cheng K, Yang X, Chang H . Targeted nanodiamonds as phenotype-specific photoacoustic contrast agents for breast cancer. Nanomedicine (Lond). 2015; 10(4):573-87. PMC: 4703108. DOI: 10.2217/nnm.14.141. View

Hofmann M, Maecke H, BORNER R, Weckesser E, Schoffski P, Oei L . Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001; 28(12):1751-7. DOI: 10.1007/s002590100639. View

10.

Laube C, Oeckinghaus T, Lehnert J, Griebel J, Knolle W, Denisenko A . Controlling the fluorescence properties of nitrogen vacancy centers in nanodiamonds. Nanoscale. 2019; 11(4):1770-1783. DOI: 10.1039/c8nr07828a. View

11.

Kaur R, Badea I . Nanodiamonds as novel nanomaterials for biomedical applications: drug delivery and imaging systems. Int J Nanomedicine. 2013; 8:203-20. PMC: 3544342. DOI: 10.2147/IJN.S37348. View

12.

Stout D, Berr S, LeBlanc A, Kalen J, Osborne D, Price J . Guidance for methods descriptions used in preclinical imaging papers. Mol Imaging. 2013; 12(7):1-15. View

13.

Liu Y, Chang B, Chang H . Nanodiamond-enabled biomedical imaging. Nanomedicine (Lond). 2020; 15(16):1599-1616. DOI: 10.2217/nnm-2020-0091. View

14.

Xiao K, Li Y, Luo J, Lee J, Xiao W, Gonik A . The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011; 32(13):3435-46. PMC: 3055170. DOI: 10.1016/j.biomaterials.2011.01.021. View

15.

DaSilva J, Decristoforo C, Mach R, Bormans G, Carlucci G, Al-Qahtani M . Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharm Chem. 2023; 8(1):35. PMC: 10611660. DOI: 10.1186/s41181-023-00218-y. View

16.

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

17.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

18.

Greish K . Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010; 624:25-37. DOI: 10.1007/978-1-60761-609-2_3. View

19.

Xu L, Raabe M, Zegota M, Nogueira J, Chudasama V, Kuan S . Site-selective protein modification via disulfide rebridging for fast tetrazine/trans-cyclooctene bioconjugation. Org Biomol Chem. 2020; 18(6):1140-1147. DOI: 10.1039/c9ob02687h. View

20.

Tai Y, Ruangma A, Rowland D, Siegel S, Newport D, Chow P . Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med. 2005; 46(3):455-63. View